Börse Express – health binx receives CE mark for rapid test for chlamydia and gonorrhea for mass markets


BOSTON, June 5 / PRNewswire / – binx health (TM), the global health leader, today announced that the company's chlamydia and gonorrhea (CT / NG) test has received European CE certification. The new multiple test uses the binx io platform to provide a lab quality result in approximately 30 minutes. This is a new model of testing and treatment in the treatment of two of the most common sexually transmitted diseases these days.

Binx io ® multi-test panel for treatment platform for radical reduction of treatment time and better care

Every day, there are more than one million sexually transmitted infections worldwide. Chlamydia and gonorrhea are among the most common.1 Data recently published by the European Center for Disease Prevention and Control (ECDC) show a large increase in gonorrhea cases in EU / EEA countries between 2016 and 2017, in 17% between 2016 and 2017. Some countries reported increases of more than 40 percent year-over-year.2 Similarly, infection rates in the US have increased 67 percent since 2013. In the 20-24 age bracket, numbers are still higher. 3

Currently, most CT / NG tests are sent to central laboratories. This means that from the first consultation until the treatment can take up to seven days, in which patients could pass the infection. In addition, up to 40% of patients with positive results do not return to treatment.4 Binx positioned itself to radically alter these conditions. Patients and consumers can leave pharmacies, doctors' offices, clinics, emergency departments and other health facilities after a single treatment visit. (Although the binx treatment platform is not yet available in the US, the company has recently completed its multi-site clinical trial for FDA approval under Section 510 (k).) The binx io platform is user-friendly and easy to use. training in the laboratory performing a test with the same accuracy as the tests in the central laboratory. This makes it ideal for use in a variety of drug and consumer acceptable environments.

"Getting a diagnosis of two of the most common sexually transmitted diseases in 30 minutes is a major breakthrough in the field of public health," said Dr. Howard Heller, MPH, Medical Director of Binx Health. "Delivering fast results means fast and appropriate treatment, and this new panel will pave the way for testing and treatment not only on the same day, but on the same visit, breaking a major barrier to treatment and cure."

"Modern health needs tools that meet the needs of consumers where they live, work and shop," said Jeffrey Luber, CEO of binx health. "Doing this effectively means delivering fast, accurate and cost-effective solutions in multiple locations, as well as online medical indexing tests that will free consumers from worry and recovery when it's convenient for them." Now we are beginning with scientific precision. standardized testing and customer focus to provide high quality care of all forms for general health, starting with young and sexually transmitted diseases. "

About binx healthbinx health (TM)

is a pioneer in caring for patients wherever they live, work and shop. We do this by: (1) Legally protected high-speed desktop PCR instruments for pharmacies, emergency care, doctors' offices, clinics, and all other locations where on-site testing and rapid results with accuracy comparable to lab tests are critical; Mobile home testing solutions that puts you in the hands of consumers to get rid of worries and improve. We begin with sexually transmitted diseases and seek to reverse the trend of increasing infections among young people. It follows more general health care, expanding our practice and domestic offerings. Binx healthcare investors include Johnson & Johnson Innovation, Novartis Venture Fund, Venture Capital LSP, BB Biotech, RMI Investments and Technology Venture Partners and strategic investor Consort Medical (its wholly-owned subsidiary Bespak, the multi-owner low cartridges cost) Company), as well as China's Bionech from Wondfo.

1 Facts of WHO, February 28, 2019

3 [2] Division of STD Prevention, [3] National Center for the Prevention of HIV / AIDS, Viral Hepatitis, STD and TB, [4] Centers for Disease Control and Prevention
4 Gift, Thomas L. et al. Tran's sex: [5] April 1999 – Vol. 26 – Condition 4 – pp. 232-240

% 2F% 2Fc212.net% 2Fc% 2Flink% 2F% 3Ft% 3D0% 26l% 3Den% 26o% 3D2452460-1% 26h% 3D3 98928791% 26u% 3Dhttps% 253A% 252F% 252Fecdc.europa.eu% 252Fen% Times% 262% 3DEDCD% 2BEUROPE & a = ECD C + EUROPE
% 2F% 2Fc212.net% 2Fc% 2Flink% 2F% 3Ft% 3D0% 26l% 3Den% 26o% 3D2452460-1% 26h% 3D1 828350347% 26u% 3Dhttps% 253A% 252F% 252Fwww.cdc.gov% 252Fstd% 252Fdst% 26a% 3DDivision% 2Bof% 2BSTD% 2BPrevention & a = Division of + STD Prevention +
% 2F% 2Fc212.net% 2Fc% 2Flink% 2F% 3Ft% 3D0% 26l% 3Den% 26o% 3D2452460-1% 26h% 3D1 774383253% 26u% 3Dhttps% 253A% 252F% 252Fwww.cdc.gov% 252Fnchhstp% 3ND% 2Benter% 2BHIV% 252FAIDS% 252C% 2BViral% 2Bepatitis% 252C% 2B% 2Band% 2BTB% 2BPrevention & National Center for HIV% 2FAIDS% 2C + V iral + Hepatitis% 2C + DST% 2C + and + TB + Prevention
F% 2Fc212.net% 2Fc% 2Flink% 2F% 3Ft% 3D0% 26l% 3Den% 26o% 3D2452460-1% 26h% 3D357 9834158% 26u% 3Dhttps% 253A% 252F% 252Fwww.cdc.gov% 252F% 26a% 3DCenters % 2BDisease% 2BControl% 2Band% Prevention & a = Centers + for + Diseases + Control l + e + Prevention
2F% 2Fc212.net% 2Fc% 2Flink% 2F% 3Ft% 3D0% 26l% 3Den% 26o% 3D2452460-1% 26h% 3D40 95280197% 26u% 3Dhttps% 253A% 252F% 252Fjournals.lww.com% 252Fstdjournal% 25 2Ftoc% 252F1999% 252F04000% 26a% 3DApril% 2B1999% 2BVolume% 2B26% 2B% 2BI% 2B4% 2B% 2Bp% 2B232% 25E2% 2580% 2593240 & a = April + 1999 + – + Band + 26 + – + Question + 4 +% E2% 80% 93 + S + 232% E2% 80% 93240

Logo – https://mma.prnewswire.com/media/880236/binx_Logo.jpg


Source link